2017年1月加拿大2016/17年度甲型（H3N2）流感疫苗有效性的中期评估。
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
作者信息
Skowronski Danuta M, Chambers Catharine, Sabaiduc Suzana, Dickinson James A, Winter Anne-Luise, De Serres Gaston, Drews Steven J, Jassem Agatha, Gubbay Jonathan B, Charest Hugues, Balshaw Robert, Bastien Nathalie, Li Yan, Krajden Mel
机构信息
British Columbia Centre for Disease Control, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.
出版信息
Euro Surveill. 2017 Feb 9;22(6). doi: 10.2807/1560-7917.ES.2017.22.6.30460.
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.
加拿大哨兵执业者监测网络（SPSN）采用检测阴性设计，评估了2016/17年度流感疫苗针对与3C.2a疫苗株抗原匹配的优势甲型（H3N2）流感病毒的中期有效性（VE）。序列分析显示，新出现的3C.2a1变体在不同省份和不同时间存在显著异质性。总体调整后的疫苗效力为42%（95%置信区间：18 - 59%），因省份而异。此处报告的中期病毒学和疫苗效力研究结果值得进一步调查，以为潜在的疫苗重新配方提供依据。
Zotero 插件